GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Avinger Inc (STU:VG20) » Definitions » EV-to-Revenue

Avinger (STU:VG20) EV-to-Revenue : -0.12 (As of Sep. 21, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Avinger EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Avinger's enterprise value is €-0.84 Mil. Avinger's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was €6.88 Mil. Therefore, Avinger's EV-to-Revenue for today is -0.12.

The historical rank and industry rank for Avinger's EV-to-Revenue or its related term are showing as below:

STU:VG20' s EV-to-Revenue Range Over the Past 10 Years
Min: -0.41   Med: 1.77   Max: 194.45
Current: -0.13

During the past 12 years, the highest EV-to-Revenue of Avinger was 194.45. The lowest was -0.41. And the median was 1.77.

STU:VG20's EV-to-Revenue is ranked better than
97.46% of 826 companies
in the Medical Devices & Instruments industry
Industry Median: 3.15 vs STU:VG20: -0.13

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-09-21), Avinger's stock price is €4.92. Avinger's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was €6.01. Therefore, Avinger's PS Ratio for today is 0.82.


Avinger EV-to-Revenue Historical Data

The historical data trend for Avinger's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avinger EV-to-Revenue Chart

Avinger Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.61 3.68 3.85 1.24 1.78

Avinger Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.02 1.72 1.78 1.90 0.07

Competitive Comparison of Avinger's EV-to-Revenue

For the Medical Instruments & Supplies subindustry, Avinger's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avinger's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Avinger's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Avinger's EV-to-Revenue falls into.



Avinger EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Avinger's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=-0.836/6.877
=-0.12

Avinger's current Enterprise Value is €-0.84 Mil.
Avinger's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.88 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avinger  (STU:VG20) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Avinger's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=4.92/6.014
=0.82

Avinger's share price for today is €4.92.
Avinger's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €6.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avinger EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Avinger's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Avinger Business Description

Traded in Other Exchanges
Address
400 Chesapeake Drive, Redwood City, CA, USA, 94063
Avinger Inc is a United States-based medical device company. It is engaged in designing, manufacturing and selling image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease (PAD). The products offered by the firm include Lightbox imaging console, the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO) and Pantheris, image-guided atherectomy device which is designed to allow physicians to precisely remove arterial plaque in PAD patients. It manufactures and sells products in the United States and internationally of which it generates the majority of the revenue from the sales made in the United States.

Avinger Headlines

No Headlines